BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco

NEW YORK, Oct. 18, 2017 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s Chief Medical Officer and Head of Business Development, Dr. Ramon Mohanlal, M.D., Ph.D., has been selected to give a presentation at this year’s BIO Investor Forum on Wednesday, Oct. 18, at 11 a.m. local time in Elizabethan D at the Westin St. Francis in San Francisco, Calif.

Dr. Mohanlal will primarily discuss BeyondSpring’s immuno-oncology product development strategy, which employs a novel and scalable business model that integrates clinical resources in both the U.S. and China to create maximum value for patients and physicians. He will also give a brief update on the current non-small cell lung cancer (NSCLC) and CIN program. BeyondSpring has advanced its lead asset, Plinabulin, into a global Phase 3 clinical trial for NSCLC treatment and Phase 2/3 clinical trials for the prevention of neutropenia, a common side effect of chemotherapy in cancer patients.

“The checkpoint inhibitor combination, PD1+CTLA4, is known to have superior efficacy over PD1 or CTLA4 alone,” said Dr. Mohanlal. “However, this comes at the price of increased immune-related adverse events (IR-AEs). When these IR-AEs are of severe grade, they typically lead to permanent discontinuation of checkpoint inhibitors. BeyondSpring’s immuno-oncology development strategy is directed to maximize efficacy, while preventing IR-AEs, by combining Plinabulin with the PD1+CTLA4 inhibitor combination.”

The 2017 BIO Investor Forum will take place on Oct. 17 through 18.

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical program in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

About Plinabulin
Studies on Plinabulin’s method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company’s future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207 /